About Utepreva LLC

Utepreva LLC is a New York–based company established in 2020. The company is responsible for the manufacturing and commercialization of the Utepreva device. Utepreva LLC is led by CEO Dr. Jeanetta Stega and Chief Financial & Medical Officer 

Dr. Damian Stega, who jointly oversee strategic development, regulatory execution, and operational leadership.


Utepreva LLC works in close partnership with the Utepreva Distribution Company, which manages all national sales activities for the device. The distribution arm is guided by experienced commercial leaders, Tom Muscarella and Peter Faulisi, ensuring strong market reach and effective deployment across clinical and healthcare networks.

The Rising Concern

Rising Incidence

Absence of Standard Screening

Rising Incidence

Uterine Cancer is the most common type of gynecologic cancer. It's estimated that about 65,950 new diagnosed in 2022, and by 2030 this number will rise to 122,000.
Uterine cancer is rapidly becoming a public health crisis. 

Survival Rates

Absence of Standard Screening

Rising Incidence

Diagnosis today typically occurs only after symptom onset (e.g., post-menopausal bleeding), most cases are already at risk of being advanced. Survival rates reach up to 95% when caught early but fall below 20% for advanced stages.

Absence of Standard Screening

Absence of Standard Screening

Absence of Standard Screening

There is currently no standardized approach for routine early detection. This creates a substantial unmet need and exposes patients to preventable morbidity, mortality, and cost escalation.

Utepreva Device

About Utepreva Endometrial Sampler

Utepreva is directly aligned with the strategic priorities being amplified by global industry leaders: improving early detection, expanding equitable access, and addressing one of the most overlooked gaps in women’s cancer care. As a patented, single-use device designed specifically for rapid, in-office uterine sampling, Utepreva enables clinicians to perform the procedure quickly, safely, and cost-effectively—without the need for specialized equipment or operating room. This allows the device to fit seamlessly into routine clinical workflow and makes widescale adoption feasible across a broad range of healthcare settings, from large health systems to community practices.

Utepreva’s tissue collection is achieved through a unique combination of suction, disruption, and absorption, enabling high-quality retrieval of both cellular and fluid-based samples.  

Contact Us

Drop us a line!

Attach Files
Attachments (0)

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

100 Jericho Quadrangle, Jericho, NY, USA

Subscribe

Utepreva LLC

Copyright © 2025 Utepreva - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept